Page 453 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

16. ANTHRACYCLINES UTILISÉES EN THÉRAPEUTIQUE 409

LING Y. H. et al., Apoptosis induced by anthracycline antibiotics in P388 parent and
multidrug resistant cells, Cancer Res., 1993, 53, 18451852.
SKLADANOWSKI A. et al., Adriamycin and daunomycin induce programmed cell death
(apoptosis) in tumeur cells, Biochem. Pharmacol., 1993, 46, 375-382.
CULLINANE, C. et al., Formation of adriamycin-DNA adductsin vitro, Nucleic Acids Res.,
1994, 22, 2296-2303.
FORNARI F.A. et al., lnterference by doxorubicin with DNA unwinding in MCF-7 breast
tumor cells, Mol. Pharmacol., 1994, 45, 649656.
FORNARI, Jr. F.A. et al., Induction of differentiation and growth arrest associated with
nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-
7 human breast tumor cells after continuous exposure to a sublethal concentration of
doxorubicin, Ce// Growth Differ., 1994, 5, 723-733.
SKLADANOWSKI A., KONOPA J., lnterstrand DNA cross-linking induced by anthracy-
clines in tumeur cells, Biochem. Pharmaco/., 1994, 47, 2269-2278.
CUTTS S. M. et al., Use of oligonucleotides ta define the site of interstrand cross-links
induced by adriamycin, Nucleic Acids Res., 1995, 23, 2450-2456.
VAN ROSMALEN A. et al., Stability of adriamycin-induced DNA adducts and interstrand
cross-links, Nucleic Acids Res., 1995, 23, 42-50.
FORNARI Jr. F.A. et al., Growth arrest and non-apoptotic cell death associated with the
suppression of c-myc expression in MCF-7 breast tumor cells following acute expo-
sure to doxorubicin, Biochem. Pharmacol., 1996, 51, 931940.
LENG F. et al., Base specific and regioselective chemical cross-linking of daunorubicin
ta DNA, J. Am. Chem. Soc., 1996, 118, 4731-4738.
LING Y. H. et al., Cell cycle dependent cytotoxicity, G2/M phase arrest, and disruption
of p34cc?/cyclin B, activity induced by doxorubicin in synchronized P388 cells, Mol.
Pharmacol., 1996, 49, 832841.
TAATJES D. J. et al., Alkylation of DNA by the anthracycline, antitumor drugs adriamycin
and daunomycin, J. Med. Chem., 1996, 39, 4135-4138.
FENICK D.J. et al., Doxoform and daunoform : anthracycline-formaldehyde conjugates
taxie to resistant tumor cells, J. Med. Chem., 1997, 40, 2452-2461.
TAATJES D. J. et al., Redox pathway leadingto the alkylation of DNA by the anthracycline
antitumor drugs adriamycin and daunomycin, JI. Med. Chem., 1997, 40, 1276-1286.
TAATJES D.J. et al., Production of formaldehyde and DNA-adriamycin or DNA-dauno-
mycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxi-
dase/NADH/iron or glutathione/iron, Chem. Res. Toxicol. ,1997, 10, 953-961.
BACHUR N.R. et al., Anthracycline antibiotic blockade of SV40 T antigen helicase
action., Biochem. Pharmaco/., 1998, 55, 1025-1034.
CHAIRES J.B. et al., Drug DNA interactions. Cur. Opin. in Struc. Bi0l., 1998, 8, 314-320.
GEWIRTZ D.A., A critical evaluation of the mechanisms of action proposed for the anti-
tumor affects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem.
Pharmacol., 1999, 57, 727-741.
INAGAKI R. et al., Anticancer drugs inhibit induction of NO synthase in rat in vivo, Gen.
Pharmacol., 1999, 32, 185-188.
SERAFINO A. et al., Induction of apoptosis in neoplastic cells by anthracycline antitumor
drugs : Nuclear and cytoplasmic triggering ?, AnticancerRes., 1999, 19 (3A4), 1909-1918.